AR064878A1 - Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto. - Google Patents
Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto.Info
- Publication number
- AR064878A1 AR064878A1 ARP080100143A ARP080100143A AR064878A1 AR 064878 A1 AR064878 A1 AR 064878A1 AR P080100143 A ARP080100143 A AR P080100143A AR P080100143 A ARP080100143 A AR P080100143A AR 064878 A1 AR064878 A1 AR 064878A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocycloalkyl
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 208000007502 anemia Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 15
- 125000003118 aryl group Chemical group 0.000 abstract 12
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- -1 -NR5R6 Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 abstract 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88471007P | 2007-01-12 | 2007-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064878A1 true AR064878A1 (es) | 2009-04-29 |
Family
ID=39636631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100143A AR064878A1 (es) | 2007-01-12 | 2008-01-11 | Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7608621B2 (https=) |
| EP (2) | EP2124565B1 (https=) |
| JP (1) | JP5313925B2 (https=) |
| KR (1) | KR101458655B1 (https=) |
| CN (1) | CN101626685B (https=) |
| AR (1) | AR064878A1 (https=) |
| AU (1) | AU2008206441B2 (https=) |
| BR (1) | BRPI0806566A2 (https=) |
| CA (1) | CA2675252C (https=) |
| CL (1) | CL2008000066A1 (https=) |
| DK (1) | DK2124565T3 (https=) |
| EA (1) | EA017112B1 (https=) |
| ES (2) | ES2528745T3 (https=) |
| HR (1) | HRP20150119T1 (https=) |
| MX (1) | MX2009007548A (https=) |
| PL (1) | PL2124565T3 (https=) |
| PT (1) | PT2124565E (https=) |
| SI (1) | SI2124565T1 (https=) |
| TW (1) | TW200845991A (https=) |
| WO (1) | WO2008089052A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI336260B (en) * | 2002-07-25 | 2011-01-21 | Glaxo Group Ltd | Dosage form suitable for retaining drug substance |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| ITMI20051085A1 (it) * | 2005-06-10 | 2006-12-11 | Acs Dobfar Spa | Metodo di purificazione del cefotetan |
| US8450351B2 (en) * | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| PT2294066E (pt) | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| WO2010025087A1 (en) * | 2008-08-25 | 2010-03-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2010055884A1 (ja) * | 2008-11-13 | 2010-05-20 | 日本農薬株式会社 | ピラジン誘導体類の製造方法及びその中間体類 |
| JP5649584B2 (ja) | 2008-11-14 | 2015-01-07 | フィブロジェン インコーポレイテッド | Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体 |
| DE102009004061A1 (de) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| EP3594213A1 (en) * | 2009-07-17 | 2020-01-15 | Japan Tobacco Inc. | Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers |
| WO2011048611A1 (en) * | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| KR101665749B1 (ko) * | 2009-10-21 | 2016-10-12 | 다이이찌 산쿄 가부시키가이샤 | 5-하이드록시피리미딘-4-카르복사미드 유도체 |
| RS54010B1 (sr) | 2009-11-06 | 2015-10-30 | Aerpio Therapeutics Inc. | Inhibitori prolil hidroksilaze |
| WO2011115687A2 (en) * | 2010-03-19 | 2011-09-22 | Northwestern University | Alkylated sp-b peptoid compounds and related lung surfactant compositions |
| WO2012106472A1 (en) | 2011-02-02 | 2012-08-09 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| NO2686520T3 (https=) | 2011-06-06 | 2018-03-17 | ||
| WO2012170439A1 (en) | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| WO2013063221A1 (en) | 2011-10-25 | 2013-05-02 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
| TWI583670B (zh) | 2012-07-30 | 2017-05-21 | 大正製藥股份有限公司 | Partially saturated nitrogenous heterocyclic compounds |
| JP2016521747A (ja) | 2013-06-13 | 2016-07-25 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 貧血治療のための組成物及び方法 |
| ES2799582T3 (es) | 2013-11-08 | 2020-12-18 | Incyte Holdings Corp | Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa |
| MY180626A (en) | 2013-11-15 | 2020-12-03 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| WO2016034108A1 (zh) | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| US10150734B2 (en) | 2015-01-23 | 2018-12-11 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CA3001065A1 (en) | 2015-10-14 | 2017-04-20 | Xiaoxi WEI | Compositions and methods for reducing ice crystal formation |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
| WO2021127273A1 (en) * | 2019-12-20 | 2021-06-24 | Gb004, Inc. | 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections |
| WO2022179967A1 (en) | 2021-02-23 | 2022-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Vadadustat for treating covid-19 in a hospitalized subject |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE149485T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| US6972296B2 (en) * | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| DE10059418A1 (de) | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DK2298301T3 (en) | 2001-12-06 | 2018-10-01 | Fibrogen Inc | MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| AU2003225088A1 (en) | 2002-04-19 | 2003-11-03 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US7718624B2 (en) | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| AU2006254897A1 (en) * | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a HIF-alpha stabilising agent |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| HRP20130044T1 (hr) | 2006-07-25 | 2013-02-28 | Cephalon, Inc. | Derivati piridizinona |
| WO2008040002A2 (en) | 2006-09-28 | 2008-04-03 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for hif modulating compounds |
| US20100003190A1 (en) | 2006-12-08 | 2010-01-07 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN) |
| WO2009142732A2 (en) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
-
2008
- 2008-01-10 TW TW097100936A patent/TW200845991A/zh unknown
- 2008-01-10 CL CL200800066A patent/CL2008000066A1/es unknown
- 2008-01-11 EA EA200970680A patent/EA017112B1/ru not_active IP Right Cessation
- 2008-01-11 ES ES08727581.4T patent/ES2528745T3/es active Active
- 2008-01-11 MX MX2009007548A patent/MX2009007548A/es active IP Right Grant
- 2008-01-11 AR ARP080100143A patent/AR064878A1/es active IP Right Grant
- 2008-01-11 HR HRP20150119TT patent/HRP20150119T1/hr unknown
- 2008-01-11 US US11/972,702 patent/US7608621B2/en not_active Ceased
- 2008-01-11 CN CN2008800073024A patent/CN101626685B/zh not_active Expired - Fee Related
- 2008-01-11 DK DK08727581.4T patent/DK2124565T3/en active
- 2008-01-11 ES ES14196983.2T patent/ES2614355T3/es active Active
- 2008-01-11 AU AU2008206441A patent/AU2008206441B2/en not_active Ceased
- 2008-01-11 SI SI200831409T patent/SI2124565T1/sl unknown
- 2008-01-11 EP EP08727581.4A patent/EP2124565B1/en active Active
- 2008-01-11 CA CA2675252A patent/CA2675252C/en active Active
- 2008-01-11 EP EP14196983.2A patent/EP2889289B1/en not_active Not-in-force
- 2008-01-11 PL PL08727581T patent/PL2124565T3/pl unknown
- 2008-01-11 PT PT08727581T patent/PT2124565E/pt unknown
- 2008-01-11 KR KR1020097016748A patent/KR101458655B1/ko active Active
- 2008-01-11 JP JP2009545699A patent/JP5313925B2/ja not_active Expired - Fee Related
- 2008-01-11 BR BRPI0806566-7A patent/BRPI0806566A2/pt not_active IP Right Cessation
- 2008-01-11 WO PCT/US2008/050833 patent/WO2008089052A2/en not_active Ceased
-
2011
- 2011-10-26 US US13/281,965 patent/USRE44613E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| USRE44613E1 (en) | 2013-11-26 |
| ES2614355T3 (es) | 2017-05-30 |
| US20080214549A1 (en) | 2008-09-04 |
| AU2008206441A1 (en) | 2008-07-24 |
| CN101626685A (zh) | 2010-01-13 |
| JP2010515756A (ja) | 2010-05-13 |
| SI2124565T1 (sl) | 2015-04-30 |
| US7608621B2 (en) | 2009-10-27 |
| EP2124565B1 (en) | 2015-01-07 |
| PT2124565E (pt) | 2015-03-26 |
| BRPI0806566A2 (pt) | 2014-05-06 |
| EP2889289A1 (en) | 2015-07-01 |
| CL2008000066A1 (es) | 2008-08-01 |
| WO2008089052A2 (en) | 2008-07-24 |
| EA200970680A1 (ru) | 2010-02-26 |
| EP2889289B1 (en) | 2016-12-21 |
| KR20090101376A (ko) | 2009-09-25 |
| KR101458655B1 (ko) | 2014-11-05 |
| HRP20150119T1 (hr) | 2015-05-08 |
| EA017112B1 (ru) | 2012-09-28 |
| EP2124565A2 (en) | 2009-12-02 |
| MX2009007548A (es) | 2009-07-22 |
| EP2124565A4 (en) | 2011-06-29 |
| JP5313925B2 (ja) | 2013-10-09 |
| CN101626685B (zh) | 2013-03-13 |
| CA2675252C (en) | 2015-05-26 |
| DK2124565T3 (en) | 2015-02-09 |
| PL2124565T3 (pl) | 2015-05-29 |
| ES2528745T3 (es) | 2015-02-12 |
| TW200845991A (en) | 2008-12-01 |
| AU2008206441B2 (en) | 2014-06-19 |
| CA2675252A1 (en) | 2008-07-24 |
| WO2008089052A3 (en) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064878A1 (es) | Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto. | |
| AR061570A1 (es) | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto | |
| CU20160030A7 (es) | Compuestos éteres de arilo yútiles para tratar cancer de célula renal | |
| PE20191078A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina utiles en el tratamiento del cancer | |
| MA42232B1 (fr) | Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| AR056785A1 (es) | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS | |
| AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
| CO6761374A2 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR126912A1 (es) | Compuestos de 6-aminopirazolopirimidina y su uso médico | |
| DOP2013000276A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR078522A1 (es) | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis | |
| NZ626314A (en) | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections | |
| AR084935A1 (es) | Derivados de tipo azaindazol o diazaindazol como medicamentos | |
| AR064877A1 (es) | Derivados de glicina n-sustituidos: inhibidores de prolil hidroxilasa | |
| PE20091972A1 (es) | Compuestos heterociclicos como inhibidores del factor ixa | |
| PE20160194A1 (es) | Composiciones y metodos para tratar anemia | |
| BR112014025564A8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| TW200800945A (en) | Macrocylic inhibitors of hepatitis c virus | |
| AR061663A1 (es) | Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados. | |
| BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
| AR076645A1 (es) | Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales. | |
| BR112016027778A2 (pt) | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |